TY - JOUR
T1 - Development of a novel c-MET-Based CTC detection platform
AU - Zhang, Tian
AU - Boominathan, Rengasamy
AU - Foulk, Brad
AU - Rao, Chandra
AU - Kemeny, Gabor
AU - Strickler, John H.
AU - Abbruzzese, James L.
AU - Harrison, Michael R.
AU - Hsu, David S.
AU - Healy, Patrick
AU - Li, Jing
AU - Pi, Cinthia
AU - Prendergast, Katherine M.
AU - Hobbs, Carey
AU - Gemberling, Sarah
AU - George, Daniel J.
AU - Hurwitz, Herbert I.
AU - Connelly, Mark
AU - Garcia-Blanco, Mariano A.
AU - Armstrong, Andrew J.
N1 - Publisher Copyright:
© 2016 American Association for Cancer Research.
PY - 2016/6
Y1 - 2016/6
N2 - Amplification of the MET oncogene is associated with poor prognosis, metastatic dissemination, and drug resistance in many malignancies. We developed a method to capture and characterize circulating tumor cells (CTC) expressing c-MET using a ferromagnetic antibody. Immunofluorescence was used to characterize cells for c-MET, DAPI, and pan-CK, excluding CD45 leukocytes. The assay was validated using appropriate cell line controls spiked into peripheral blood collected from healthy volunteers (HV). In addition, peripheral blood was analyzed from patients with metastatic gastric, pancreatic, colorectal, bladder, renal, or prostate cancers. CTCs captured by c-MET were enumerated, and DNA FISH for MET amplification was performed. The approach was highly sensitive (80%) for MET-amplified cells, sensitive (40%-80%) for c-MET-overexpressed cells, and specific (100%) for both c-MET-negative cells and in 20 HVs. Of 52 patients with metastatic carcinomas tested, c-MET CTCs were captured in replicate samples from 3 patients [gastric, colorectal, and renal cell carcinoma (RCC)] with 6% prevalence. CTC FISH demonstrated that MET amplification in both gastric and colorectal cancer patients and trisomy 7 with gain of MET gene copies in the RCC patient. The c-MET CTC assay is a rapid, noninvasive, sensitive, and specific method for detecting MET-amplified tumor cells. CTCs with MET amplification can be detected in patients with gastric, colorectal, and renal cancers. Implications: This study developed a novel c-MET CTC assay for detecting c-MET CTCs in patients with MET amplification and warrants further investigation to determine its clinical applicability.
AB - Amplification of the MET oncogene is associated with poor prognosis, metastatic dissemination, and drug resistance in many malignancies. We developed a method to capture and characterize circulating tumor cells (CTC) expressing c-MET using a ferromagnetic antibody. Immunofluorescence was used to characterize cells for c-MET, DAPI, and pan-CK, excluding CD45 leukocytes. The assay was validated using appropriate cell line controls spiked into peripheral blood collected from healthy volunteers (HV). In addition, peripheral blood was analyzed from patients with metastatic gastric, pancreatic, colorectal, bladder, renal, or prostate cancers. CTCs captured by c-MET were enumerated, and DNA FISH for MET amplification was performed. The approach was highly sensitive (80%) for MET-amplified cells, sensitive (40%-80%) for c-MET-overexpressed cells, and specific (100%) for both c-MET-negative cells and in 20 HVs. Of 52 patients with metastatic carcinomas tested, c-MET CTCs were captured in replicate samples from 3 patients [gastric, colorectal, and renal cell carcinoma (RCC)] with 6% prevalence. CTC FISH demonstrated that MET amplification in both gastric and colorectal cancer patients and trisomy 7 with gain of MET gene copies in the RCC patient. The c-MET CTC assay is a rapid, noninvasive, sensitive, and specific method for detecting MET-amplified tumor cells. CTCs with MET amplification can be detected in patients with gastric, colorectal, and renal cancers. Implications: This study developed a novel c-MET CTC assay for detecting c-MET CTCs in patients with MET amplification and warrants further investigation to determine its clinical applicability.
UR - http://www.scopus.com/inward/record.url?scp=84975086229&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84975086229&partnerID=8YFLogxK
U2 - 10.1158/1541-7786.MCR-16-0011
DO - 10.1158/1541-7786.MCR-16-0011
M3 - Article
C2 - 26951228
AN - SCOPUS:84975086229
SN - 1541-7786
VL - 14
SP - 539
EP - 547
JO - Molecular Cancer Research
JF - Molecular Cancer Research
IS - 6
ER -